Clinical trials: Stage 2 Hypertension
Pulmonary Artery Hypertension
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the…
- Trial name
- NCT02684786
- Testing
- reserpine, stellate ganglion block, lidocaine
- Where
- United States
- Sponsor
- Mayo Clinic
Hypertension
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
- Trial name
- NCT00325962
- Testing
- 6R-BH4 (sapropterin dihydrochloride)
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- BioMarin Pharmaceutical
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Hypertension
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
Essential hypertension (HTN) is a disease that affects approximately 1 billion individuals worldwide. Despite the availability of effective and safe anti-hypertensive drugs, 65% of subjects diagnosed with HTN do not have their…
- Trial name
- NEW-HOPE (NCT03198793)
- Testing
- QGC001
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Quantum Genomics SA
Pulmonary Arterial Hypertension
Beta-blockers in Pulmonary Arterial Hypertension
The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection…
- Trial name
- NCT02507011
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Minnesota
HCC, Liver Cirrhosis
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically…
- Conditions
- HCC, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT07350070
- Testing
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Tongji Hospital
Hypertension
Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions
The combination of the diuretics amiloride hydrochloride (HCl) and hydrochlorothiazide (HCTZ) (GSK3542503) is indicated for the treatment of hypertension, congestive heart failure and hepatic cirrhosis with ascites and edema.
- Trial name
- NCT03031496
- Testing
- GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets), Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
- Where
- South Africa
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
The prevalence of arterial hypertension has remained the same in the last 5 years, however, almost 50% of the population continues without an adequate adjustment according to the National Health Survey of the Midway 2016.
- Trial name
- NCT03592667
- Testing
- Dapagliflozin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- University of Guadalajara
Stasis Dermatitis
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment…
- Trial name
- NCT04091087
- Testing
- crisaborole ointment, vehicle ointment
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pfizer
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Group 3 Pulmonary Hypertension
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat.
- Trial name
- WINDWARD (NCT06475781)
- Testing
- Mirivadelgat
- Where
- 11 sites in Bosnia and Herzegovina, Taiwan
- Volunteers
- 126 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Diabetes, Hypertensive Disease
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
Diabetes is the leading cause of chronic kidney disease in developed countries. About 30-40% of patients with type 1 and type 2 diabetes mellitus will develop diabetic nephropathy.
- Trial name
- eGFR (NCT01500590)
- Testing
- Renin-angiotensin system blockers, non-renin angiotensin system blockers
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Hospital Authority, Hong Kong
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
The primary objective of the study is to: Evaluate the safety and tolerability of REGN5381 and REGN9035 administered alone or sequentially.
- Trial name
- NCT05291546
- Testing
- REGN9035, REGN5381
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Ocular Hypertension, Open Angle Glaucoma
A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to test if latanoprost punctal plugs will reduce eye pressure in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT01229982
- Testing
- Latanoprost-PPDS
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Mati Therapeutics Inc.
Pre-hypertension, JNC 7 Stage I Hypertension
Center of Research Translation (CORT) Project 2
We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout.
- Trial name
- NCT02038179
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes Mellitus, Hypertension
Vitamin D and Omega-3 Inhibit Metabolic Syndrome
The study will test the hypothesis that supplementing the diet of subjects with Metabolic Syndrome with 2000 IU vitamin D and 1.8 g omega-3 fatty acids (EPA + DHA) per day, will facilitate weight loss, improve body composition…
- Conditions
- Type 2 Diabetes Mellitus, Hypertension, Hyperlipidemia, Obesity
- Trial name
- NCT01326442
- Testing
- low glycemic diet, vitamin D omega-3
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Guelph
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Hypertension
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension
The purpose of this study is to determine the safety and efficacy of azilsartan, once daily (QD), in subjects with essential hypertension.
- Trial name
- NCT00759551
- Testing
- Azilsartan, Olmesartan
- Volunteers
- 555 people
- Sponsor
- Takeda